What Simtra BioPharma Solutions does

Simtra BioPharma Solutions is a privately held contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products. The company was carved out of Baxter's BioPharma Solutions business in October 2023 when private equity firms Advent International and Warburg Pincus acquired the unit for $4.25 billion and rebranded it as Simtra. It serves 60+ pharmaceutical and biotechnology clients across more than 120 countries, offering end-to-end services from formulation development through clinical and commercial manufacturing, including biologics, monoclonal antibodies, vaccines, antibody-drug conjugates (ADCs), cytotoxics, highly potent compounds, small molecules, and diluents.

The company's core technology centers on aseptic fill/finish operations, lyophilization, and specialized containment for cytotoxic and high-potency active pharmaceutical ingredients. It operates two flagship, cGMP-compliant campuses: a 600,000-square-foot headquarters and manufacturing site in Bloomington, Indiana, and an award-winning facility in Halle/Westfalen, Germany. Proprietary capabilities include a Lyophilization Center of Excellence using a 'quality-by-design' design-space methodology, open and closed RABS/isolator-based containment technologies with SafeBridge certification, multi-tier cold-chain filling and storage (from -70°C to +25°C, monitored 24/7), and comprehensive analytical services spanning chromatography, mass spectrometry, and spectroscopy.

Simtra operates a pure B2B, professional services revenue model, with project-based contracts negotiated per client requirements and delivered through dedicated cross-functional account teams. The company sells exclusively through direct enterprise sales and, more recently, through strategic channel partnerships such as the five-year ADC alliance with MilliporeSigma (Merck KGaA). Customer segments split between large pharmaceutical/biotech companies lacking internal sterile manufacturing capacity and smaller emerging biotechs needing end-to-end development-to-commercialization support. Pricing is quote-based and not publicly disclosed. The company is privately held and not subject to public revenue reporting.

Name

Simtra BioPharma Solutions

Legal name

Baxter Pharmaceutical Solutions LLC d/b/a Simtra BioPharma Solutions

Website

https://simtra.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Simtra BioPharma Solutions is a privately held CDMO specializing in sterile injectable contract manufacturing, including fill/finish, lyophilization, and containment for cytotoxics, biologics, vaccines, and antibody-drug conjugates, serving 60+ pharmaceutical and biotech clients across 120+ countries from facilities in Indiana, USA and Halle/Westfalen, Germany.

Ownership category

akta.pro rank

Product category

Sterile Injectable Contract Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Sterile injectable manufacturing
• Pharmaceutical CDMO services
• Lyophilization cycle development
• Aseptic fill-finish operations
• Biologics and ADC manufacturing

Headquarters

HQ city

Parsippany

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Simtra generates revenue through contract development and manufacturing services for sterile injectable products. Services include formulation development, lyophilization, fill/finish operations, analytical services, and regulatory support from clinical through commercial production stages. Revenue is project-based with dedicated client teams.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Simtra BioPharma Solutions is a contract development and manufacturing organization (CDMO) that develops and manufactures sterile injectable pharmaceutical products for pharmaceutical and biotechnology clients. Services span formulation development, lyophilization cycle development, rapid technology transfer, aseptic fill/finish operations, specialized containment for cytotoxic and highly potent compounds, analytical services, and global regulatory support, delivered as liquid vials, lyophilized vials, and prefilled syringes from cGMP-compliant facilities in the USA and Germany.

Differentiator

Problem solved

Functional benefit

Products and services

• Formulation Development

Quantifiable outcome

• 65+ years of manufacturing experience with 60+ clients
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• MilliporeSigma (Life Science business of Merck KGaA, Darmstadt, Germany)coreStrategic or Co-development Partner · 1 June 2025Five-year strategic alliance for integrated antibody-drug conjugate (ADC) drug substance and drug product manufacturing. The partnership enables seamless coordination, shared project management, and quality-first ADC manufacturing. Simtra provides drug product fill/finish services while MilliporeSigma provides conjugation services, including linker and payload capabilities. The alliance streamlines supply chains and reduces complexity for pharma and biopharma companies developing ADCs.

Scale indicators9 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Catalent: One of the largest global CDMOs with a sizeable sterile injectable fill/finish business, overlapping directly with Simtra across biologics, vaccines, and highly potent compounds for pharma and biotech clients.
• Lonza Group: Leading biologics and sterile injectable CDMO offering mammalian and microbial manufacturing, fill/finish, and development services — competing directly for the same large-pharma and biotech programs as Simtra.
• Aenova Group: German-headquartered CDMO with strong sterile injectable and high-potency capabilities; competes most directly with Simtra's Halle facility for European pharma contracts.
• Recipharm: European CDMO focused on sterile injectables, biologics fill/finish, and small molecule manufacturing — a close comparable in customer base and service mix to Simtra.
• Fareva: Private European CDMO with sterile injectable and biologics capabilities, including high-potent handling, overlapping with Simtra's cytotoxic and complex injectable offering.
• PCI Pharma Services: Global CDMO with significant sterile injectable fill/finish and clinical-to-commercial manufacturing services, competing with Simtra for pharmaceutical outsourcing contracts.
• GRAM (Grand River Aseptic Manufacturing): US-based sterile injectable CDMO with strong fill/finish capacity growth, competing with Simtra's Bloomington operations for North American pharma and biotech contracts.

Broad incumbents

• Thermo Fisher Scientific (Pharma Services / Patheon): Operates one of the largest sterile injectable CDMO businesses via the Patheon franchise alongside broader pharma services, overlapping with Simtra in fill/finish, biologics, and clinical-to-commercial manufacturing.

Emerging players

• Samsung Biologics: Large-scale biologics CDMO rapidly expanding into sterile fill/finish, increasingly competing with Simtra for global commercial biologics manufacturing contracts.
• WuXi STA (WuXi AppTec): China-based CDMO offering sterile injectable and biologics services, increasingly competing for global ADC and fill/finish programs though constrained by US/Biosecure-related geopolitical headwinds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@simtrabiopharma
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/simtra-biopharma-solutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Simtra BioPharma Solutions